title: Treatment of metastatic hormone-refractory prostate adenocarcinoma (MatLyLu) in Copenhagen rats with micro-osmotic interleukin-2 pumps.
abstract: BACKGROUND
  We studied the influence of interleukin-2 (IL-2) therapy on tumor growth and prevention of metastasis in metastatic, hormone-refractory prostatic carcinoma (PCa) in an animal model orthotopically (ortho) and subcutaneously (s.c.).
  
  
  METHODS
  75 juvenile male Copenhagen rats were divided into five groups of 15 rats each. MatLyLu-PCa (MLL) was implanted ortho (n = 30) in 2 groups or s.c. (n = 30) in 2 groups and were treated locally at the tumor site with micro-osmotic pumps. The rats in 2 groups received IL-2 pumps with 36 x 10(6) IU of IL-2 and the rats in 2 other groups were treated with pumps delivering albumin only as a control. The rats in the last group received ortho MLL and s.c. IL-2 (n = 15). Survival time was then monitored.
  
  
  RESULTS
  Prostatic tumor was found in all ortho animals. Additionally lymphogenic and pulmonary metastasis was found in all animals. The orthotopic and s.c. IL-2-treated groups showed a statistically significantly increased survival compared with the orthotopic and s.c. albumin-treated groups. When treating the ortho MLL with s.c. IL-2 there was still a statistically significant longer survival than in the control groups.
  
  
  CONCLUSIONS
  IL-2 therapy significantly reduces tumor growth of rats with metastatic, hormone-refractory prostatic cancer MatLyLu.
authors.affiliation: Department of Urology, University Hospital Hamburg-Eppendorf, Martintistr. 52, 20246 Hamburg, Germany. stefanhautmann@yahoo.com
authors.forename: S
authors.initials: S
authors.lastname: Hautmann
authors.forename: E
authors.initials: E
authors.lastname: Huland
authors.forename: A
authors.initials: A
authors.lastname: Wullbrand
authors.forename: M
authors.initials: M
authors.lastname: Friedrich
authors.forename: H
authors.initials: H
authors.lastname: Huland
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality / Q000556:secondary; D000818:Animals; D015918:Infusion Pumps, Implantable; D007376:Interleukin-2 / Q000008:administration & dosage*; D008175:Lung Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D009368:Neoplasm Transplantation; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D051381:Rats; D014407:Tumor Cells, Cultured
chemical_list: D007376:Interleukin-2